Systematic literature review and meta-analysis of US-approved LAMA/LABA therapies versus tiotropium in moderate-to-severe COPD View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-12

AUTHORS

MeiLan K. Han, Riju Ray, Jason Foo, Chaienna Morel, Beth Hahn

ABSTRACT

Dual bronchodilator maintenance therapy may benefit patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) versus long-acting muscarinic antagonist (LAMA) monotherapy. The efficacy and safety of US-approved LAMA/long-acting beta-agonist (LABA) combinations versus tiotropium (TIO), a LAMA, were assessed. This systematic review and meta-analysis (GSK: 206938), conducted in MEDLINE, MEDLINE In-process, and EMBASE following Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines, identified randomized clinical trials (>8 weeks) in moderate-to-severe COPD (per Global Initiative for Chronic Obstructive Lung Disease guidelines), receiving LAMA/LABA or TIO. ENDPOINTS: difference in change from baseline in lung function (forced expiratory volume in 1 s [FEV1]; trough, peak, area under the curve 0-3 h post-dose (AUC0-3), St George's Respiratory Questionnaire (SGRQ) responder rate (≥4-unit improvement), SGRQ total score, and rescue medication use at 12 and 24 weeks. Safety was also assessed. From 5683 citations, the meta-analysis included eight clinical trials. LAMA/LABA significantly improved FEV1 trough (Week 12: 63.0 mL, 95% confidence intervals [CI]: 39.2, 86.8; Week 24: 66.1 mL, 95% CI: 40.0, 92.3), peak (Week 12: 91.5 mL, 95% CI: 70.5, 112.4; Week 24: 92.4 mL, 95% CI: 72.9, 111.9), AUC0-3 (Week 12: 126.8 mL, 95% CI: 108.1, 145.4), SGRQ responder rate at Week 12 (risk ratio: 1.19; 95% CI: 1.09, 1.28), mean SGRQ total score (Week 12: -1.87, 95% CI: -2.72, -1.02; Week 24: -1.05, 95% CI: -2.02, -0.09), and rescue medication use (Week 24: -0.47 puffs/day, 95% CI: -0.64, -0.30) versus TIO (all p ≤ 0.03). The SGRQ responder rate at 24 weeks and adverse events were not significantly different between treatments. US-approved LAMA/LABA therapies improved lung function, SGR,Q and rescue medication use versus TIO, without compromising safety. More... »

PAGES

32

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/s41533-018-0099-1

DOI

http://dx.doi.org/10.1038/s41533-018-0099-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1106295037

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30150639


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Michigan\u2013Ann Arbor", 
          "id": "https://www.grid.ac/institutes/grid.214458.e", 
          "name": [
            "University of Michigan, Ann Arbor, MI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Han", 
        "givenName": "MeiLan K.", 
        "id": "sg:person.01300353273.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300353273.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "GSK Research, Triangle Park, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ray", 
        "givenName": "Riju", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Mapi Group, Houten, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Foo", 
        "givenName": "Jason", 
        "id": "sg:person.016705275167.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016705275167.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Mapi Group, Houten, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Morel", 
        "givenName": "Chaienna", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "GSK Research, Triangle Park, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hahn", 
        "givenName": "Beth", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.2147/copd.s87082", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004411858"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/thoraxjnl-2014-206732", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004673127"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/thoraxjnl-2014-206732", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004673127"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1164/ajrccm/145.6.1321", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008761947"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.rmed.2014.10.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011888243"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1164/rccm.201505-1048oc", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012267356"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2147/copd.s54417", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012428650"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.rmed.2015.08.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012629940"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1183/09031936.00136014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013653436"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1183/09031936.00136014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013653436"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1183/09031936.00136014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013653436"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.chest.2016.11.028", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024401270"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.chest.2016.11.028", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024401270"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1081/copd-200050513", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034934253"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s2213-2600(14)70065-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037998562"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/14651858.cd008989.pub3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039736655"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1164/ajrccm.157.5.9709032", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041155061"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1081/copd-120030163", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050498875"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078937312", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2147/copd.s119032", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084386308"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2147/copd.s130482", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084386333"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.15326/jcopdf.4.3.2017.0136", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090222423"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-12", 
    "datePublishedReg": "2018-12-01", 
    "description": "Dual bronchodilator maintenance therapy may benefit patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) versus long-acting muscarinic antagonist (LAMA) monotherapy. The efficacy and safety of US-approved LAMA/long-acting beta-agonist (LABA) combinations versus tiotropium (TIO), a LAMA, were assessed. This systematic review and meta-analysis (GSK: 206938), conducted in MEDLINE, MEDLINE In-process, and EMBASE following Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines, identified randomized clinical trials (>8 weeks) in moderate-to-severe COPD (per Global Initiative for Chronic Obstructive Lung Disease guidelines), receiving LAMA/LABA or TIO.\nENDPOINTS: difference in change from baseline in lung function (forced expiratory volume in 1\u2009s [FEV1]; trough, peak, area under the curve 0-3\u2009h post-dose (AUC0-3), St George's Respiratory Questionnaire (SGRQ) responder rate (\u22654-unit improvement), SGRQ total score, and rescue medication use at 12 and 24 weeks. Safety was also assessed. From 5683 citations, the meta-analysis included eight clinical trials. LAMA/LABA significantly improved FEV1 trough (Week 12: 63.0\u2009mL, 95% confidence intervals [CI]: 39.2, 86.8; Week 24: 66.1\u2009mL, 95% CI: 40.0, 92.3), peak (Week 12: 91.5\u2009mL, 95% CI: 70.5, 112.4; Week 24: 92.4\u2009mL, 95% CI: 72.9, 111.9), AUC0-3 (Week 12: 126.8\u2009mL, 95% CI: 108.1, 145.4), SGRQ responder rate at Week 12 (risk ratio: 1.19; 95% CI: 1.09, 1.28), mean SGRQ total score (Week 12: -1.87, 95% CI: -2.72, -1.02; Week 24: -1.05, 95% CI: -2.02, -0.09), and rescue medication use (Week 24: -0.47 puffs/day, 95% CI: -0.64, -0.30) versus TIO (all p\u2009\u2264\u20090.03). The SGRQ responder rate at 24 weeks and adverse events were not significantly different between treatments. US-approved LAMA/LABA therapies improved lung function, SGR,Q and rescue medication use versus TIO, without compromising safety.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/s41533-018-0099-1", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1294845", 
        "issn": [
          "1471-4418", 
          "2055-1010"
        ], 
        "name": "Primary Care Respiratory Journal", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "28"
      }
    ], 
    "name": "Systematic literature review and meta-analysis of US-approved LAMA/LABA therapies versus tiotropium in moderate-to-severe COPD", 
    "pagination": "32", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "3064f1b7396f79e2e82ebee5db884ab2c391a10ba45a39e4d3ae490203f4a53e"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30150639"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101631999"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/s41533-018-0099-1"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1106295037"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/s41533-018-0099-1", 
      "https://app.dimensions.ai/details/publication/pub.1106295037"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T13:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8659_00000566.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://www.nature.com/articles/s41533-018-0099-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/s41533-018-0099-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/s41533-018-0099-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/s41533-018-0099-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/s41533-018-0099-1'


 

This table displays all metadata directly associated to this object as RDF triples.

155 TRIPLES      21 PREDICATES      47 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/s41533-018-0099-1 schema:about anzsrc-for:11
2 anzsrc-for:1102
3 schema:author N07473ddbc6e7403e8dc15207fd7104ab
4 schema:citation https://app.dimensions.ai/details/publication/pub.1078937312
5 https://doi.org/10.1002/14651858.cd008989.pub3
6 https://doi.org/10.1016/j.chest.2016.11.028
7 https://doi.org/10.1016/j.rmed.2014.10.002
8 https://doi.org/10.1016/j.rmed.2015.08.002
9 https://doi.org/10.1016/s2213-2600(14)70065-7
10 https://doi.org/10.1081/copd-120030163
11 https://doi.org/10.1081/copd-200050513
12 https://doi.org/10.1136/thoraxjnl-2014-206732
13 https://doi.org/10.1164/ajrccm.157.5.9709032
14 https://doi.org/10.1164/ajrccm/145.6.1321
15 https://doi.org/10.1164/rccm.201505-1048oc
16 https://doi.org/10.1183/09031936.00136014
17 https://doi.org/10.15326/jcopdf.4.3.2017.0136
18 https://doi.org/10.2147/copd.s119032
19 https://doi.org/10.2147/copd.s130482
20 https://doi.org/10.2147/copd.s54417
21 https://doi.org/10.2147/copd.s87082
22 schema:datePublished 2018-12
23 schema:datePublishedReg 2018-12-01
24 schema:description Dual bronchodilator maintenance therapy may benefit patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) versus long-acting muscarinic antagonist (LAMA) monotherapy. The efficacy and safety of US-approved LAMA/long-acting beta-agonist (LABA) combinations versus tiotropium (TIO), a LAMA, were assessed. This systematic review and meta-analysis (GSK: 206938), conducted in MEDLINE, MEDLINE In-process, and EMBASE following Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines, identified randomized clinical trials (>8 weeks) in moderate-to-severe COPD (per Global Initiative for Chronic Obstructive Lung Disease guidelines), receiving LAMA/LABA or TIO. ENDPOINTS: difference in change from baseline in lung function (forced expiratory volume in 1 s [FEV1]; trough, peak, area under the curve 0-3 h post-dose (AUC0-3), St George's Respiratory Questionnaire (SGRQ) responder rate (≥4-unit improvement), SGRQ total score, and rescue medication use at 12 and 24 weeks. Safety was also assessed. From 5683 citations, the meta-analysis included eight clinical trials. LAMA/LABA significantly improved FEV1 trough (Week 12: 63.0 mL, 95% confidence intervals [CI]: 39.2, 86.8; Week 24: 66.1 mL, 95% CI: 40.0, 92.3), peak (Week 12: 91.5 mL, 95% CI: 70.5, 112.4; Week 24: 92.4 mL, 95% CI: 72.9, 111.9), AUC0-3 (Week 12: 126.8 mL, 95% CI: 108.1, 145.4), SGRQ responder rate at Week 12 (risk ratio: 1.19; 95% CI: 1.09, 1.28), mean SGRQ total score (Week 12: -1.87, 95% CI: -2.72, -1.02; Week 24: -1.05, 95% CI: -2.02, -0.09), and rescue medication use (Week 24: -0.47 puffs/day, 95% CI: -0.64, -0.30) versus TIO (all p ≤ 0.03). The SGRQ responder rate at 24 weeks and adverse events were not significantly different between treatments. US-approved LAMA/LABA therapies improved lung function, SGR,Q and rescue medication use versus TIO, without compromising safety.
25 schema:genre research_article
26 schema:inLanguage en
27 schema:isAccessibleForFree true
28 schema:isPartOf N5f4f10f554cd44c5a4f7006a5a7514d6
29 Nb4c38f5da4b548099ef7608685438a9f
30 sg:journal.1294845
31 schema:name Systematic literature review and meta-analysis of US-approved LAMA/LABA therapies versus tiotropium in moderate-to-severe COPD
32 schema:pagination 32
33 schema:productId N0a6bbf78db964c08b7ac3ae046a20c27
34 N1758ea1a80544d659fa2e49213688b5b
35 N60451f9b78784baabe8f0df7e5e9047c
36 Nac0ba4210172413ca6ab4bf2f6538205
37 Ncc2fa8f5b3ea45e3b4a337f1b68fa00e
38 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106295037
39 https://doi.org/10.1038/s41533-018-0099-1
40 schema:sdDatePublished 2019-04-10T13:27
41 schema:sdLicense https://scigraph.springernature.com/explorer/license/
42 schema:sdPublisher N13db0b6a824643809351de6ad08c6209
43 schema:url https://www.nature.com/articles/s41533-018-0099-1
44 sgo:license sg:explorer/license/
45 sgo:sdDataset articles
46 rdf:type schema:ScholarlyArticle
47 N07473ddbc6e7403e8dc15207fd7104ab rdf:first sg:person.01300353273.80
48 rdf:rest Necd23945e7814ab0aade2f9099680cea
49 N0a6bbf78db964c08b7ac3ae046a20c27 schema:name dimensions_id
50 schema:value pub.1106295037
51 rdf:type schema:PropertyValue
52 N12104800285f4f068624a247c9c2127f schema:affiliation N4f0570b127d945a4b8272db2ae8295fe
53 schema:familyName Ray
54 schema:givenName Riju
55 rdf:type schema:Person
56 N13db0b6a824643809351de6ad08c6209 schema:name Springer Nature - SN SciGraph project
57 rdf:type schema:Organization
58 N1758ea1a80544d659fa2e49213688b5b schema:name pubmed_id
59 schema:value 30150639
60 rdf:type schema:PropertyValue
61 N39a188ddef98434e8787bfd769d06b6b schema:affiliation Neacf4e269a5d40b7b0f48dd6c9e368b6
62 schema:familyName Hahn
63 schema:givenName Beth
64 rdf:type schema:Person
65 N4f0570b127d945a4b8272db2ae8295fe schema:name GSK Research, Triangle Park, NC, USA
66 rdf:type schema:Organization
67 N5f4f10f554cd44c5a4f7006a5a7514d6 schema:issueNumber 1
68 rdf:type schema:PublicationIssue
69 N60451f9b78784baabe8f0df7e5e9047c schema:name readcube_id
70 schema:value 3064f1b7396f79e2e82ebee5db884ab2c391a10ba45a39e4d3ae490203f4a53e
71 rdf:type schema:PropertyValue
72 Na84348e3b36e463f9db941a566e7dbe1 rdf:first Nd5191c82783b4b168868c32da3518311
73 rdf:rest Nfcf9f559952c4259918fb7df58a786f0
74 Nac0ba4210172413ca6ab4bf2f6538205 schema:name doi
75 schema:value 10.1038/s41533-018-0099-1
76 rdf:type schema:PropertyValue
77 Nb4c38f5da4b548099ef7608685438a9f schema:volumeNumber 28
78 rdf:type schema:PublicationVolume
79 Nb7cfc531ee304aaa9f2f9116aff6b1ab schema:name Mapi Group, Houten, The Netherlands
80 rdf:type schema:Organization
81 Nc75d80eca88746129b0ab7fc752f7981 schema:name Mapi Group, Houten, The Netherlands
82 rdf:type schema:Organization
83 Ncc2fa8f5b3ea45e3b4a337f1b68fa00e schema:name nlm_unique_id
84 schema:value 101631999
85 rdf:type schema:PropertyValue
86 Nd5191c82783b4b168868c32da3518311 schema:affiliation Nc75d80eca88746129b0ab7fc752f7981
87 schema:familyName Morel
88 schema:givenName Chaienna
89 rdf:type schema:Person
90 Ne4b189cd4f0145f282caf648b2c28532 rdf:first sg:person.016705275167.57
91 rdf:rest Na84348e3b36e463f9db941a566e7dbe1
92 Neacf4e269a5d40b7b0f48dd6c9e368b6 schema:name GSK Research, Triangle Park, NC, USA
93 rdf:type schema:Organization
94 Necd23945e7814ab0aade2f9099680cea rdf:first N12104800285f4f068624a247c9c2127f
95 rdf:rest Ne4b189cd4f0145f282caf648b2c28532
96 Nfcf9f559952c4259918fb7df58a786f0 rdf:first N39a188ddef98434e8787bfd769d06b6b
97 rdf:rest rdf:nil
98 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
99 schema:name Medical and Health Sciences
100 rdf:type schema:DefinedTerm
101 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
102 schema:name Cardiorespiratory Medicine and Haematology
103 rdf:type schema:DefinedTerm
104 sg:journal.1294845 schema:issn 1471-4418
105 2055-1010
106 schema:name Primary Care Respiratory Journal
107 rdf:type schema:Periodical
108 sg:person.01300353273.80 schema:affiliation https://www.grid.ac/institutes/grid.214458.e
109 schema:familyName Han
110 schema:givenName MeiLan K.
111 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300353273.80
112 rdf:type schema:Person
113 sg:person.016705275167.57 schema:affiliation Nb7cfc531ee304aaa9f2f9116aff6b1ab
114 schema:familyName Foo
115 schema:givenName Jason
116 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016705275167.57
117 rdf:type schema:Person
118 https://app.dimensions.ai/details/publication/pub.1078937312 schema:CreativeWork
119 https://doi.org/10.1002/14651858.cd008989.pub3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039736655
120 rdf:type schema:CreativeWork
121 https://doi.org/10.1016/j.chest.2016.11.028 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024401270
122 rdf:type schema:CreativeWork
123 https://doi.org/10.1016/j.rmed.2014.10.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011888243
124 rdf:type schema:CreativeWork
125 https://doi.org/10.1016/j.rmed.2015.08.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012629940
126 rdf:type schema:CreativeWork
127 https://doi.org/10.1016/s2213-2600(14)70065-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037998562
128 rdf:type schema:CreativeWork
129 https://doi.org/10.1081/copd-120030163 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050498875
130 rdf:type schema:CreativeWork
131 https://doi.org/10.1081/copd-200050513 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034934253
132 rdf:type schema:CreativeWork
133 https://doi.org/10.1136/thoraxjnl-2014-206732 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004673127
134 rdf:type schema:CreativeWork
135 https://doi.org/10.1164/ajrccm.157.5.9709032 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041155061
136 rdf:type schema:CreativeWork
137 https://doi.org/10.1164/ajrccm/145.6.1321 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008761947
138 rdf:type schema:CreativeWork
139 https://doi.org/10.1164/rccm.201505-1048oc schema:sameAs https://app.dimensions.ai/details/publication/pub.1012267356
140 rdf:type schema:CreativeWork
141 https://doi.org/10.1183/09031936.00136014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013653436
142 rdf:type schema:CreativeWork
143 https://doi.org/10.15326/jcopdf.4.3.2017.0136 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090222423
144 rdf:type schema:CreativeWork
145 https://doi.org/10.2147/copd.s119032 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084386308
146 rdf:type schema:CreativeWork
147 https://doi.org/10.2147/copd.s130482 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084386333
148 rdf:type schema:CreativeWork
149 https://doi.org/10.2147/copd.s54417 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012428650
150 rdf:type schema:CreativeWork
151 https://doi.org/10.2147/copd.s87082 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004411858
152 rdf:type schema:CreativeWork
153 https://www.grid.ac/institutes/grid.214458.e schema:alternateName University of Michigan–Ann Arbor
154 schema:name University of Michigan, Ann Arbor, MI, USA
155 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...